FIRST AMENDMENT TO THE RESEARCH COLLABORATION AGREEMENT
Exhibit 10.15
FIRST AMENDMENT TO THE
RESEARCH COLLABORATION AGREEMENT
This First Amendment (the “First Amendment”), effective as February 20, 2019, to that certain Research Collaboration Agreement (the “Agreement” and incorporated herein by reference) effective December 20, 2018, among APRINOIA Therapeutics Inc. (“APN”), a company having an office at 00X, Xx.0, Xxxx Xx., Xxxxxxx Xxxxxxxx, Xxxxxx Xxxx 00000, Xxxxxx, and X. Xxxxxxxx A/S (“Lundbeck’’), having an office at XxxxXxxxxx 0, Xxxxx, 0000, Xxxxxxx, and AbbVic Inc. (“AbbVic”), a company having an office at 0 X Xxxxxxxx Xx, Xxxxx Xxxxxxx. IL, USA (each a “Party” and collectively, “Parties”).
Subject to the full execution of this First Amendment, APN, Lundbeck and AbbVie hereby agree to the following amendments:
1. | Following compounds are added to Appendix II: |
[***]
2. | This First Amendment shall form an integral part of the Agreement and shall be regarded incorporated into the Agreement in every respect. |
3. | Except as specifically amended hereby, all provisions of the Agreement shall remain in full force and effect. |
IN WITNESS WHEREOF the Parties have executed and delivered this Agreement by their duly authorized representatives as of the Effective Date.
APRINOIA Therapeutics Inc. | X. Xxxxxxxx A/S | ||||
By: | /s/ Xxxx-Xxxx Xxxx | By: | /s/ Xxxxx Xxxx Xxxxxxxx | ||
Name: | Xxxx-Xxxx Xxxx | Name: | Xxxxx Xxxx Xxxxxxxx | ||
Title: | CEO | Title: | VP | ||
Date: | Feb 26, 2019 | Date: | 25/2/2019 |
AbbVie Inc. | |||
By: | /s/ Xxxxxxxx X. Xxxxx, X.X. | ||
Name: | Xxxxxxxx X. Xxxxx, X.X. | ||
Title: | Head Technology Licensing & Collaborations | ||
Date: | 2-23-2019 |